Literature DB >> 18716976

Trichomegaly induced by erlotinib.

Rebecca Papadopoulos1, Vasiliki Chasapi, Alexandre Bachariou.   

Abstract

Erlotinib (Tarceva, Roche) is a chemotherapeutic agent used in the management of advanced non-small cell lung cancer and other malignancies. We present the case of a patient who developed excessive eyelash growth, called trichomegaly, a rare ocular side effect of this drug.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18716976     DOI： 10.1080/01676830802222936

Source DB:  PubMed          Journal:  Orbit        ISSN： 0167-6830


  5 in total

1.  Follow-up of erlotinib related uveitis.

Authors:  Indu Kumar; Kashif Ali; Muniba Usman-Saeed; Muhammad Usman Saeed
Journal:  BMJ Case Rep       Date:  2012-08-14

2.  Erlotinib-related bilateral anterior uveitis.

Authors:  Kashif Ali; Indu Kumar; Muniba Usman-Saeed; Muhammad Usman Saeed
Journal:  BMJ Case Rep       Date:  2011-05-24

Review 3.  Ocular Toxicity of Targeted Anticancer Agents.

Authors:  Blake H Fortes; Prashant D Tailor; Lauren A Dalvin
Journal:  Drugs       Date:  2021-03-31       Impact factor: 9.546

4.  A murine model of dry eye induced by topical administration of erlotinib eye drops.

Authors:  Qi-Chen Yang; Jing Bao; Cheng Li; Gang Tan; An-Hua Wu; Lei Ye; Lin-Hong Ye; Qiong Zhou; Yi Shao
Journal:  Int J Mol Med       Date:  2017-12-29       Impact factor: 4.101

5.  Eyelash Trichomegaly.

Authors:  Sandeep Kaur; Bharat Bhushan Mahajan
Journal:  Indian J Dermatol       Date:  2015 Jul-Aug       Impact factor: 1.494
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.